Summary Patients with advanced solid malignancies were enrolled to an open-label, single-arm, dose-escalation study, in which CRLX101 was administered intravenously over 60 min among two dosing schedules, initially weekly at 6, 12, and 18 mg/m2 and later bi-weekly at 12, 15, and 18 mg/m2. The maximum tolerated dose (MTD) was determined at 15 mg/m2 bi-weekly, and an expansion phase 2a study was completed. Patient samples were obtained for pharmacokinetic (PK) and pharmacodynamic (PD) assessments. Response was evaluated per RECIST criteria v1.0 every 8 weeks. Sixty-two patients (31 male; median age 63 years, range 39-79) received treatment. Bi-weekly dosing was generally well tolerated with myelosuppression being the dose-limiting toxicity. Among all phase 1/2a patients receiving the MTD (n=44), most common grade 3/4 adverse events were neutropenia and fatigue. Evidence of systemic plasma exposure to both the polymer-conjugated and unconjugated CPT was observed in all treated patients. Mean elimination unconjugated CPT Tmax values ranged from 17.7 to 24.5 h, and maximum plasma concentrations and areas under the curve were generally proportional to dose for both polymer-conjugated and unconjugated CPT. Best overall response was stable disease in 28 patients (64 %) treated at the MTD and 16 (73 %) of a subset of NSCLC patients. Median progression-free survival (PFS) for patients treated at the MTD was 3.7 months and for the subset of NSCLC patients was 4.4 months. These combined phase 1/2a data demonstrate encouraging safety, pharmacokinetic, and efficacy results. Multinational phase 2 clinical development of CRLX101 across multiple tumor types is ongoing.

No abstract

Objective To describe change in sexual function 2 years after surgery to treat stress urinary incontinence. Methods This analysis included 655 women randomized to Burch colposuspension or sling surgery. Sexual activity was assessed by the PISQ-12 among those sexually active at baseline and two years after surgery. Results Mean PISQ-12 total score improved from baseline 32.23±6.85 to 36.85± 5.89. After surgery, fewer subjects reported incontinence (9% vs. 53%, p<0.0001), restriction of sexual activity due to fear of incontinence (10% vs. 52%, p<0.0001), avoidance of intercourse because of vaginal bulging (3% vs. 24%, p<0.0001) or negative emotional reactions during sex (9% vs. 35%, p<0.0001). Women with successful surgery had greater improvement PISQ-12 scores (5.77 vs. 3.79), p<0.006. Sexually active women were younger, thinner, and had lower MESA scores (total and urge subscale) than sexually inactive women. Conclusion Sexual function improves following successful surgery and did not differ between Burch or sling.

Inositol 1,4,5-trisphosphate (InsP3), a product of G-protein-mediated receptor activation of phosphoinositide turnover, plays the role of a second messenger when olfactory neurons are stimulated with certain olfactory stimuli. In this paper we examine the specific binding of [3H]InsP3 to isolated olfactory cilia, microsomes and brain membranes from the channel catfish (Ictalurus punctatus) and, by photoaffinity labelling with an InsP3 analogue (125I-labelled 1-[3-(4-azidosalicyloxy)-aminopropyl]inositol 1,4,5-trisphosphate (125I-ASA-InsP3)], we tentatively identify the major InsP3-binding protein in catfish olfactory cilia. InsP3 binding to ciliary membranes is specific and saturable, with a Kd of 1.10 +/- 0.31 microM and a maximum number of binding sites (Bmax) of 17.6 +/- 5.8 pmol/mg. The rank order for potency of inhibition of [3H]InsP3 binding is Ins(1,4)P2 less than Ins(1,3,4)P3 less than Ins(1,3,4,5)P4 = Ins(1,4,5)P3 less than Ins(2,4,5)P3. Exposure of cilia membranes to u.v. light in the presence of 125I-ASA-InsP3 results in the labelling of a protein with apparent Mr 107,000. Labelling is specifically prevented by Ins(1,4,5)P3, Ins(2,4,5)P3 and Ins(1,3,4,5)P4, but not by Ins(1,4)P2 or Ins(1,3,4)P3. Both specific [3H]InsP3 binding and photoaffinity labelling of the Mr-107,000 protein were displaced by heparin. The Kd and the inhibition of [3H]InsP3 binding and of photoaffinity labelling by inositol phosphates and heparin are consistent with the ability of micromolar concentrations of Ins(1,4,5)P3 [but not Ins(1,3,4)P3] to activate the InsP3-gated currents in patch-clamp experiments with olfactory neurons. These results suggest that InsP3 binding to a Mr-107,000 cilia membrane protein may represent binding to the olfactory InsP3-gated cation channel.